GH Research PLC (GHRS), a clinical-stage biopharmaceutical company, on Thursday announced Phase 2a results for GH001 in treating post-partum depression (PPD). Results were published in The Journal of Clinical Psychiatry.
The company's lead candidate GH001 contains mebufotenin formulated via a proprietary inhalation approach.
The Phase 2b GH001-TRD-201 trial was a single-arm, open-label study with 10 enrolled PPD patients. The primary endpoint was set at a reduction in depression measured by the Montgomery-Asberg Depression Rating Scale (MADRS).
Results indicate that the primary endpoint was met, with patients showing a mean MADRS reduction of 35.4 points from the baseline to Day 8. Additionally, 100% of patients achieved remission (MADRS less than 10) within two hours of dosing. An improvement in maternal functioning was also noted, with a mean 34.1-point increase on the Barkin Index of Maternal Functioning by Day 8. The drug was found to be well-tolerated.
The company stated that the results supported further investigation of inhaled mebufotenin in larger, randomized, placebo-controlled trials in PPD.
GH001 is being advanced in the studies for treatment-resistant depression (TRD).
GHRS closed Thursday at $23.25, down 4.83%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.